Combination chemotherapy with docetaxel plus vinorelbine in metastatic breast cancer patients with prior exposure to anthracyclines

Annals of Oncology

Volumn 12, Issue 8, 2001, Pages 1061-1065

  Marti J L ^a   Bueso, P ^a   Mayordomo, J I ^a   Isla, M D ^a   Saenz, A ^a   Escudero, P ^a   Murillo, L ^a   Filipovich, E ^a   Andres, R ^a   Tres, A ^a  

^a Hospital Universitario Miguel Servet Avda   (Spain)

Author keywords

Breast cancer; Docetaxel; Drug combination; Vinorelbine

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTHRAQUINONE; ANTINEOPLASTIC AGENT; BETA TUBULIN; BILIRUBIN; CREATININE; DEXAMETHASONE; DIPHENHYDRAMINE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; GRANISETRON; HEMOGLOBIN; MICROTUBULE PROTEIN; MITOXANTRONE; NAVELBINE; PACLITAXEL; RANITIDINE; TAXOID; VINCA ALKALOID;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; HEMATOLOGIC DISEASE; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MUCOSA INFLAMMATION; NEUTROPENIA; PATIENT SATISFACTION; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STEM CELL; SURVIVAL TIME; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT PLANNING;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CONFIDENCE INTERVALS; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; FEMALE; HUMANS; MIDDLE AGED; PACLITAXEL; TAXOIDS; TREATMENT OUTCOME; VINBLASTINE;

EID: 17944367097     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011691307995     Document Type: Article

References (20)

1. Paclitaxel: An update of its use in the treatment of metastatic breast cancer and ovarian and other gynaecological cancers
2. Docetaxel (taxotere) for the treatment of anthracycline-resistant breast cancer
3. Vinorelbine (navelbine): A third-generation vinca alkaloid
4. In vitro studies of paclitaxel in combination with either etoposide or vinorelbine: Sequence dependent effects causing synergism or antagonism
5. Vinorelbine tartrate and paclitaxel combinations: Enhanced activity against in vivo P388 murine leukemia cells
6. Preclinical evaluation of docetaxel (Taxotere)
7. Reporting results of cancer treatment
8. Southwest Oncology Group standard response criteria, endpoint definitions, and toxicity criteria
9. Final results of a phase I dose finding and pharmacokinetic (PK) study of docetaxel in combination with vinorelbine in metastatic breast cancer
10. A phase II study of docetaxel (D) and vinorelbine (V) in metastatic breast cancer (MBC)
11. Docetaxel+ vinorelbine with concurrent G-CSF support: A phase II study in stage IV breast cancer
12. Treatment of advanced breast cancer (ABC) with docetaxel and vinorelbine ± human granulocyte colony-stimulating factor (G-CSF)
13. Docetaxel and vinorelbine every 14 days in patients with metastatic breast cancer after using anthracyclines. Final results
14. Docetaxel (DOC) and navelbine (NVB) as first line chemotherapy (CT) in advanced breast cancer (ABC). A phase II study of Hellenic Cooperative Oncology Group
15. Phase II study of docetaxel and vinorelbine in heavily pretreated metastatic breast cancer
16. Weekly docetaxel plus gemcitabine or vinorelbine in refractory advanced breast cancer patients: A parallel dose-finding study
17. Docetaxel in combination with doxorubicin or vinorelbine
18. Paclitaxel plus vinorelbine: An active regimen in metastatic breast cancer patients with prior anthracycline exposure
19. Current options in treatment of anthracycline-resistant breast cancer
20. Reversible peripheral neuropathy induced by a single administration of high-dose paclitaxel